{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T04:00:59Z","timestamp":1769745659080,"version":"3.49.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["R01CE003358"],"award-info":[{"award-number":["R01CE003358"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["Fellowship award"],"award-info":[{"award-number":["Fellowship award"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"DOI":"10.1007\/s11606-025-10113-8","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:39:00Z","timestamp":1769697540000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prescription Depressant-Involved Overdose Mortality in Massachusetts (2000-2023): A Cohort Study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8803-0694","authenticated-orcid":false,"given":"Hannah","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3556-1075","authenticated-orcid":false,"given":"Huiru","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6769-2732","authenticated-orcid":false,"given":"Mohammad S.","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2286-1448","authenticated-orcid":false,"given":"Erin J.","family":"Stringfellow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"10113_CR1","doi-asserted-by":"publisher","unstructured":"Brady JE, Giglio R, Keyes KM, DiMaggio C, Li G. Risk markers for fatal and non-fatal prescription drug overdose: a meta-analysis. Inj Epidemiol. 2017;4(1):24. https:\/\/doi.org\/10.1186\/s40621-017-0118-7","DOI":"10.1186\/s40621-017-0118-7"},{"key":"10113_CR2","doi-asserted-by":"publisher","unstructured":"Carter EJR, Rine NI, Kistamgari S, et al. Gabapentin and pregabalin exposures reported to United States poison centers, 2012-2022. Inj Epidemiol. 2024;11(1):59. https:\/\/doi.org\/10.1186\/s40621-024-00547-9","DOI":"10.1186\/s40621-024-00547-9"},{"key":"10113_CR3","doi-asserted-by":"publisher","unstructured":"Gibson CJ, Li Y, Jasuja GK, Keyhani S, Byers AL. Long-term psychoactive medications, polypharmacy, and risk of suicide and unintended overdose death among midlife and older women veterans. J Gen Intern Med. 2022;37(Suppl 3):770-777. https:\/\/doi.org\/10.1007\/s11606-022-07592-4","DOI":"10.1007\/s11606-022-07592-4"},{"key":"10113_CR4","doi-asserted-by":"publisher","unstructured":"Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML. Association between polypharmacy and death: A systematic review and meta-analysis. J Am Pharm Assoc JAPhA. 2017;57(6):729-738.e10. https:\/\/doi.org\/10.1016\/j.japh.2017.06.002","DOI":"10.1016\/j.japh.2017.06.002"},{"key":"10113_CR5","doi-asserted-by":"publisher","unstructured":"Wastesson JW, Morin L, Tan ECK, Johnell K. An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf. 2018;17(12):1185-1196. https:\/\/doi.org\/10.1080\/14740338.2018.1546841","DOI":"10.1080\/14740338.2018.1546841"},{"key":"10113_CR6","doi-asserted-by":"publisher","unstructured":"Domzaridou E, Carr MJ, Millar T, Webb RT, Ashcroft DM. Non-fatal overdose risk associated with prescribing opioid agonists concurrently with other medication: Cohort study conducted using linked primary care, secondary care and mortality records. Addiction. 2023;118(12):2374-2383. https:\/\/doi.org\/10.1111\/add.16306","DOI":"10.1111\/add.16306"},{"key":"10113_CR7","doi-asserted-by":"publisher","unstructured":"Kelly BC, Wells BE, Pawson M, LeClair A, Parsons JT. Combinations of prescription drug misuse and illicit drugs among young adults. Addict Behav. 2014;39(5):941-944. https:\/\/doi.org\/10.1016\/j.addbeh.2013.12.003","DOI":"10.1016\/j.addbeh.2013.12.003"},{"key":"10113_CR8","doi-asserted-by":"publisher","unstructured":"Liu S, Vivolo-Kantor A. A latent class analysis of drug and substance use patterns among patients treated in emergency departments for suspected drug overdose. Addict Behav. 2020;101. https:\/\/doi.org\/10.1016\/j.addbeh.2019.106142","DOI":"10.1016\/j.addbeh.2019.106142"},{"key":"10113_CR9","doi-asserted-by":"publisher","unstructured":"Park JN, Schneider KE, Fowler D, Sherman SG, Mojtabai R, Nestadt PS. Polysubstance Overdose Deaths in the Fentanyl Era: A Latent Class Analysis. J Addict Med. 2022;16(1):49-55. https:\/\/doi.org\/10.1097\/ADM.0000000000000823","DOI":"10.1097\/ADM.0000000000000823"},{"key":"10113_CR10","doi-asserted-by":"publisher","unstructured":"Thomas SA, Wagner KD, Clements-Nolle KD, Omaye S, Lu M, Yang W. Associations between circumstances surrounding overdose and underlying classes of polysubstance overdose deaths. Subst Use Misuse. 2023;58(3):434-443. https:\/\/doi.org\/10.1080\/10826084.2023.2165414","DOI":"10.1080\/10826084.2023.2165414"},{"key":"10113_CR11","doi-asserted-by":"publisher","unstructured":"Terplan M. Women and the opioid crisis: historical context and public health solutions. Fertil Steril. 2017;108(2):195-199. https:\/\/doi.org\/10.1016\/j.fertnstert.2017.06.007","DOI":"10.1016\/j.fertnstert.2017.06.007"},{"key":"10113_CR12","unstructured":"Arthur Hughes, Matthew R. Williams, Rachel N. Lipari, Jonaki Bose. Prescription drug use and misuse in the United States: Results from the 2015 National Survey on Drug Use and Health.; 2016. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/NSDUH-FFR2-2015\/NSDUH-FFR2-2015.htm"},{"key":"10113_CR13","doi-asserted-by":"publisher","unstructured":"Wightman RS, Perrone J, Scagos R, et al. Toxicological and pharmacologic sex differences in unintentional or undetermined opioid overdose death. Drug Alcohol Depend. 2021;227:108994. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108994","DOI":"10.1016\/j.drugalcdep.2021.108994"},{"key":"10113_CR14","doi-asserted-by":"publisher","unstructured":"Tardelli VS, Bianco MCM, Prakash R, et al. Overdose deaths involving non-BZD hypnotic\/sedatives in the USA: Trends analyses. Lancet Reg Health \u2013 Am. 2022;10. https:\/\/doi.org\/10.1016\/j.lana.2022.100190","DOI":"10.1016\/j.lana.2022.100190"},{"key":"10113_CR15","doi-asserted-by":"publisher","unstructured":"Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and misuse of pregabalin and gabapentin: A systematic review update. Drugs. 2021;81(1):125-156. https:\/\/doi.org\/10.1007\/s40265-020-01432-7","DOI":"10.1007\/s40265-020-01432-7"},{"key":"10113_CR16","doi-asserted-by":"publisher","unstructured":"Ellis MS, Xu KY, Tardelli VS, Fidalgo TM, Buttram ME, Grucza RA. Gabapentin use among individuals initiating buprenorphine treatment for opioid use disorder. JAMA Psychiatry. 2023;80(12):1269-1276. https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.3145","DOI":"10.1001\/jamapsychiatry.2023.3145"},{"key":"10113_CR17","doi-asserted-by":"publisher","unstructured":"Van Norman GA. Off-label use vs Off-label marketing\u00a0of\u00a0drugs. JACC Basic Transl Sci. 2023;8(2):224-233. https:\/\/doi.org\/10.1016\/j.jacbts.2022.12.011","DOI":"10.1016\/j.jacbts.2022.12.011"},{"key":"10113_CR18","unstructured":"Massachusetts Department of Public Health. An examination of opioid related overdose deaths among Massachusetts residents. Commonwealth of Massachusetts, Executive Office of Health and Human Services; 2024. https:\/\/malegislature.gov\/Bills\/193\/HD5417.pdf"},{"key":"10113_CR19","unstructured":"World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Fifth Edition, 2016. World Health Organization; 2015. Accessed December 15, 2024. https:\/\/iris.who.int\/handle\/10665\/246208"},{"key":"10113_CR20","unstructured":"Ahmad FB, Cisewski JA, Rossen LM, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. September 17, 2025. Accessed 11 Jan 2026. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"10113_CR21","unstructured":"Massachusetts Department of Public Health. Data brief: Opioid-related overdose deaths among Massachusetts residents.; 2024. Accessed 26 July 2025. https:\/\/www.mass.gov\/doc\/opioid-related-overdose-deaths-among-ma-residents-june-2024-0\/download"},{"key":"10113_CR22","doi-asserted-by":"publisher","unstructured":"Spencer M, Cisewski J, Warner M, Garnett M. Drug overdose deaths involving xylazine, United States, 2018\u20132021. National Center for Health Statistics (U.S.); 2023. https:\/\/doi.org\/10.15620\/cdc:129519","DOI":"10.15620\/cdc:129519"},{"key":"10113_CR23","doi-asserted-by":"publisher","unstructured":"Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657-659. https:\/\/doi.org\/10.1001\/jama.2013.272","DOI":"10.1001\/jama.2013.272"},{"key":"10113_CR24","doi-asserted-by":"publisher","unstructured":"Shiue KY, Austin AE, Proescholdbell S, Cox ME, Aurelius M, Naumann RB. Literal text analysis of poly-class and polydrug overdose deaths in North Carolina, 2015\u20132019. Drug Alcohol Depend. 2021;228:109048. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.109048","DOI":"10.1016\/j.drugalcdep.2021.109048"},{"key":"10113_CR25","unstructured":"State Office of Rural Health Rural Definition. Mass.gov. March 2017. Accessed September 26, 2024. https:\/\/www.mass.gov\/info-details\/state-office-of-rural-health-rural-definition"},{"key":"10113_CR26","doi-asserted-by":"publisher","unstructured":"Weller BE, Bowen NK, Faubert SJ. Latent class analysis: A guide to best practice. J Black Psychol. 2020;46(4):287-311. https:\/\/doi.org\/10.1177\/0095798420930932","DOI":"10.1177\/0095798420930932"},{"key":"10113_CR27","doi-asserted-by":"publisher","unstructured":"Scrucca L, Saqr M, L\u00f3pez-Pernas S, Murphy K. An Introduction and R Tutorial to Model-Based Clustering in Education via Latent Profile Analysis. In: Saqr M, L\u00f3pez-Pernas S, eds. Learning Analytics Methods and Tutorials: A Practical Guide Using R. Springer Nature Switzerland; 2024:285\u2013317. https:\/\/doi.org\/10.1007\/978-3-031-54464-4_9","DOI":"10.1007\/978-3-031-54464-4_9"},{"key":"10113_CR28","unstructured":"Davis J, Sabel J, Wright D, Slavova S. Epi Tool to Analyze Overdose Death Data. 2015. Accessed December 1, 2024. https:\/\/www.cste.org\/blogpost\/1084057\/211072\/Epi-Tool-to-Analyze-Overdose-Death-Data"},{"key":"10113_CR29","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing.; 2023. https:\/\/www.R-project.org\/"},{"key":"10113_CR30","doi-asserted-by":"publisher","unstructured":"Linzer DA, Lewis JB. poLCA: An R package for polytomous variable latent class analysis. J Stat Softw. 2011;42(10):1-29. https:\/\/doi.org\/10.18637\/jss.v042.i10","DOI":"10.18637\/jss.v042.i10"},{"key":"10113_CR31","unstructured":"Centers for Disease Control and Prevention. Prescription Painkiller Overdoses: A Growing Epidemic, Especially among Women.; 2013. Accessed February 9, 2025. https:\/\/www.cdc.gov\/vitalsigns\/pdf\/2013-07-vitalsigns.pdf"},{"key":"10113_CR32","doi-asserted-by":"publisher","unstructured":"Pauly NJ, Delcher C, Slavova S, Lindahl E, Talbert J, Freeman PR. Trends in Gabapentin Prescribing in a Commercially Insured U.S. Adult Population, 2009\u20132016. J Manag Care Spec Pharm. 2020;26(3):https:\/\/doi.org\/10.18553\/jmcp.2020.26.3.246","DOI":"10.18553\/jmcp.2020.26.3.246"},{"key":"10113_CR33","doi-asserted-by":"publisher","unstructured":"Kuehn BM. Growing Role of Gabapentin in Opioid-Related Overdoses Highlights Misuse Potential and Off-label Prescribing Practices. JAMA. 2022;328(13):1283-1285. https:\/\/doi.org\/10.1001\/jama.2022.13659","DOI":"10.1001\/jama.2022.13659"},{"key":"10113_CR34","unstructured":"Halli-Tierney AD, Scarbrough C, Carroll D. Polypharmacy: Evaluating Risks and Deprescribing. Am Fam Physician. 2019;100(1):32\u201338. Accessed October 23, 2025. https:\/\/www.aafp.org\/pubs\/afp\/issues\/2019\/0701\/p32.html"},{"key":"10113_CR35","doi-asserted-by":"publisher","unstructured":"Nguyen A, Wang J, Holland KM, et al. Trends in Drug Overdose Deaths by Intent and Drug Categories, United States, 1999\u20122022. Am J Public Health. 2024;114(10):1081-1085. https:\/\/doi.org\/10.2105\/AJPH.2024.307745","DOI":"10.2105\/AJPH.2024.307745"},{"key":"10113_CR36","doi-asserted-by":"publisher","unstructured":"Ray WA, Fuchs DC, Olfson M, et al. Antipsychotic Medications and Mortality in Children and Young Adults. JAMA Psychiatry. 2024;81(3):260-269. https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.4573","DOI":"10.1001\/jamapsychiatry.2023.4573"},{"key":"10113_CR37","doi-asserted-by":"publisher","unstructured":"Curry DE, Richards BL. A Brief Review of Quetiapine. Am J Psychiatry Resid J. 2022;18(2):20-22. https:\/\/doi.org\/10.1176\/appi.ajp-rj.2022.180207","DOI":"10.1176\/appi.ajp-rj.2022.180207"},{"key":"10113_CR38","doi-asserted-by":"publisher","unstructured":"Herrarte C, Martinez M, Gonzalvo JD, Davis BT, Thoma LM, Campbell NL. Evaluation of tricyclic antidepressant deprescribing in the treatment of diabetic peripheral neuropathy within federally qualified health centers. J Am Pharm Assoc JAPhA. 2024;64(4S):102113. https:\/\/doi.org\/10.1016\/j.japh.2024.102113","DOI":"10.1016\/j.japh.2024.102113"},{"key":"10113_CR39","doi-asserted-by":"publisher","unstructured":"Taylor D, Poulou S, Clark I. The cardiovascular safety of tricyclic antidepressants in overdose and in clinical use. Ther Adv Psychopharmacol. 2024;14:20451253241243297. https:\/\/doi.org\/10.1177\/20451253241243297","DOI":"10.1177\/20451253241243297"},{"key":"10113_CR40","doi-asserted-by":"publisher","unstructured":"Richards-Belle A, Launders N, Hardoon S, et al. Prescribing of antipsychotics for people diagnosed with severe mental illness in UK primary care 2000\u20132019: 20-year investigation of who receives treatment, with which agents and at what doses. Br J Psychiatry. Published online December 18, 2024:1\u20139. https:\/\/doi.org\/10.1192\/bjp.2024.186","DOI":"10.1192\/bjp.2024.186"},{"key":"10113_CR41","doi-asserted-by":"publisher","unstructured":"Diaz FJ, De Leon J. Excessive antipsychotic dosing in 2 U.S. State hospitals. J Clin Psychiatry. 2002;63(11):998-1003. https:\/\/doi.org\/10.4088\/jcp.v63n1107","DOI":"10.4088\/jcp.v63n1107"},{"key":"10113_CR42","doi-asserted-by":"publisher","unstructured":"Wang T, Codling D, Bhugra D, et al. Unraveling ethnic disparities in antipsychotic prescribing among patients with psychosis: A retrospective cohort study based on electronic clinical records. Schizophr Res. 2023;260:168-179. https:\/\/doi.org\/10.1016\/j.schres.2023.08.024","DOI":"10.1016\/j.schres.2023.08.024"},{"key":"10113_CR43","doi-asserted-by":"publisher","unstructured":"Hall WJ, Chapman MV, Lee KM, et al. Implicit Racial\/Ethnic Bias Among Health Care Professionals and Its Influence on Health Care Outcomes: A Systematic Review. Am J Public Health. 2015;105(12):e60-e76. https:\/\/doi.org\/10.2105\/AJPH.2015.302903","DOI":"10.2105\/AJPH.2015.302903"},{"key":"10113_CR44","doi-asserted-by":"publisher","unstructured":"Sclar DA, Robison LM, Skaer TL, Dickson WM, Kozma CM, Reeder CE. Antidepressant prescribing patterns: a comparison of blacks and whites in a medicaid population. Clin Drug Investig. 1998;16(2):135-140. https:\/\/doi.org\/10.2165\/00044011-199816020-00006","DOI":"10.2165\/00044011-199816020-00006"},{"key":"10113_CR45","doi-asserted-by":"publisher","unstructured":"Hoffman KM, Trawalter S, Axt JR, Oliver MN. Racial bias in pain assessment and treatment recommendations, and false beliefs about biological differences between blacks and whites. Proc Natl Acad Sci. 2016;113(16):4296-4301. https:\/\/doi.org\/10.1073\/pnas.1516047113","DOI":"10.1073\/pnas.1516047113"},{"key":"10113_CR46","doi-asserted-by":"publisher","unstructured":"Cintron A, Morrison RS. Pain and ethnicity in the United States: A systematic review. J Palliat Med. 2006;9(6):1454-1473. https:\/\/doi.org\/10.1089\/jpm.2006.9.1454","DOI":"10.1089\/jpm.2006.9.1454"},{"key":"10113_CR47","unstructured":"Staton LJ, Panda M, Chen I, et al. When race matters: disagreement in pain perception between patients and their physicians in primary care. J Natl Med Assoc. 2007;99(5):532-538."},{"key":"10113_CR48","doi-asserted-by":"publisher","unstructured":"Cook B, Creedon T, Wang Y, et al. Examining racial\/ethnic differences in patterns of benzodiazepine prescription and misuse. Drug Alcohol Depend. 2018;187:29-34. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.02.011","DOI":"10.1016\/j.drugalcdep.2018.02.011"},{"key":"10113_CR49","doi-asserted-by":"publisher","unstructured":"Kleinman RA, Weiss RD. Benzodiazepine-Involved Overdose Deaths in the USA: 2000\u20132019. J Gen Intern Med. 2022;37(8):2103-2109. https:\/\/doi.org\/10.1007\/s11606-021-07035-6","DOI":"10.1007\/s11606-021-07035-6"},{"key":"10113_CR50","doi-asserted-by":"publisher","unstructured":"Smith MK, Planalp C, Bennis SL, et al. Widening Racial Disparities in the U.S. Overdose Epidemic. Am J Prev Med. 2025;68(4):745-753. https:\/\/doi.org\/10.1016\/j.amepre.2024.12.020","DOI":"10.1016\/j.amepre.2024.12.020"},{"key":"10113_CR51","doi-asserted-by":"publisher","unstructured":"Milani SA, Raji MA, Chen L, Kuo YF. Trends in the Use of Benzodiazepines, Z-Hypnotics, and Serotonergic Drugs Among US Women and Men Before and During the COVID-19 Pandemic. JAMA Netw Open. 2021;4(10):e2131012. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.31012","DOI":"10.1001\/jamanetworkopen.2021.31012"},{"key":"10113_CR52","unstructured":"Massachusetts Prescription Awareness Tool (MassPAT). Mass.gov. Accessed July 26, 2025. https:\/\/www.mass.gov\/guides\/massachusetts-prescription-awareness-tool-masspat"},{"key":"10113_CR53","unstructured":"Center for Drug Evaluation and Research. FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. August 31, 2016. Accessed October 23, 2025. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-about-serious-risks-and-death-when-combining-opioid-pain-or"},{"key":"10113_CR54","doi-asserted-by":"publisher","unstructured":"Bradford W, Figgatt M, Scott KS, Marshall S, Eaton EF, Dye DW. Xylazine co-occurrence with illicit fentanyl is a growing threat in the Deep South: a retrospective study of decedent data. Harm Reduct J. 2024;21(1):46. https:\/\/doi.org\/10.1186\/s12954-024-00959-2","DOI":"10.1186\/s12954-024-00959-2"},{"key":"10113_CR55","doi-asserted-by":"publisher","unstructured":"Kariisa M. Illicitly Manufactured Fentanyl\u2013Involved Overdose Deaths with Detected Xylazine \u2014 United States, January 2019\u2013June 2022. MMWR Morb Mortal Wkly Rep. 2023;72. https:\/\/doi.org\/10.15585\/mmwr.mm7226a4","DOI":"10.15585\/mmwr.mm7226a4"},{"key":"10113_CR56","unstructured":"DrugsData.org. DrugsData.org. Accessed February 9, 2025. https:\/\/www.drugsdata.org\/"},{"key":"10113_CR57","doi-asserted-by":"publisher","unstructured":"McNeilage AG, Sim A, Nielsen S, Murnion B, Ashton-James CE. Experiences of misuse and symptoms of dependence among people who use gabapentinoids: A qualitative systematic review. Int J Drug Policy. 2024;133:104605. https:\/\/doi.org\/10.1016\/j.drugpo.2024.104605","DOI":"10.1016\/j.drugpo.2024.104605"},{"key":"10113_CR58","doi-asserted-by":"publisher","unstructured":"Pinedo M. A current re-examination of racial\/ethnic disparities in the use of substance abuse treatment: Do disparities persist? Drug Alcohol Depend. 2019;202:162-167. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.05.017","DOI":"10.1016\/j.drugalcdep.2019.05.017"},{"key":"10113_CR59","unstructured":"Department of Public Health. DPH report: Massachusetts opioid-related overdose deaths decreased 10 percent in 2023. Mass.gov. https:\/\/www.mass.gov\/news\/dph-report-massachusetts-opioid-related-overdose-deaths-decreased-10-percent-in-2023. Accessed July 13, 2025."},{"key":"10113_CR60","unstructured":"Deaths of Massachusetts Residents. Population Health Information Tool, Massachusetts Department of Public Health. Accessed July 26, 2025. https:\/\/www.mass.gov\/info-details\/deaths-of-massachusetts-residents"},{"key":"10113_CR61","doi-asserted-by":"publisher","unstructured":"Adams JM. Increasing naloxone awareness and use the role of health care practitioners. JAMA - J Am Med Assoc. 2018;319(20):2073-2074. https:\/\/doi.org\/10.1001\/jama.2018.4867","DOI":"10.1001\/jama.2018.4867"},{"key":"10113_CR62","doi-asserted-by":"publisher","unstructured":"Abouk R, Pacula RL, Powell D. Association between State Laws Facilitating Pharmacy Distribution of Naloxone and Risk of Fatal Overdose. JAMA Intern Med. 2019;179(6):805-811. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0272","DOI":"10.1001\/jamainternmed.2019.0272"},{"key":"10113_CR63","doi-asserted-by":"publisher","unstructured":"Dong H, Stringfellow EJ, Russell A, Jalali MS. State Mandates On Naloxone Coprescribing Associated With Short-Term Increase In Naloxone Codispensing. Health Aff (Millwood). 2024;43(9):1319-1328. https:\/\/doi.org\/10.1377\/hlthaff.2023.01667","DOI":"10.1377\/hlthaff.2023.01667"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-10113-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-025-10113-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-10113-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:39:05Z","timestamp":1769697545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-025-10113-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":63,"alternative-id":["10113"],"URL":"https:\/\/doi.org\/10.1007\/s11606-025-10113-8","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate Declarations"}},{"value":"The authors declare that they do not have a conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}